NCT05945407 Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer
| NCT ID | NCT05945407 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University People's Hospital |
| Condition | Endometrial Neoplasms |
| Study Type | INTERVENTIONAL |
| Enrollment | 57 participants |
| Start Date | 2016-08-01 |
| Primary Completion | 2023-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 57 participants in total. It began in 2016-08-01 with a primary completion date of 2023-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to explore the feasibility and outcome of fertility-sparing therapy in Stage IA G1-G2 Endometrial Cancer with less than 1/2 myometrial invasion. Researchers will render participants indication-extended fertility-sparing therapy. Researchers will compare the myometrial invasion group with the no myometrial invasion group to see if it is possible to propose an extension indication of fertility-sparing therapy for endometrial cancer.
Eligibility Criteria
Inclusion Criteria: * Stage IA (FIGO 2009) ; * Pathological diagnosis: endometrial adenocarcinoma G1-G2; * MRI or ultrasound: tumor limited to endometrium or invading less than 1/2 of myometrium； * 18 years old ≤ Age ≤ 45 years old; * With a strong desire for fertility preservation； * Sign the informed consent. Exclusion Criteria: * Complicated with any other malignancy； * Contraindications to conservative treatment； * Contraindications to progestin use; * Contraindications to pregnancy, or judged by the researcher to be unfit for pregnancy or delivery.
Contact & Investigator
Jianliu Wang, Professor
STUDY DIRECTOR
Peking University People's Hospital
Frequently Asked Questions
Who can join the NCT05945407 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 45 Years, studying Endometrial Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05945407 currently recruiting?
Yes, NCT05945407 is actively recruiting participants. Contact the research team at wangjianliu1203@163.com for enrollment information.
Where is the NCT05945407 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT05945407 clinical trial?
NCT05945407 is sponsored by Peking University People's Hospital. The principal investigator is Jianliu Wang, Professor at Peking University People's Hospital. The trial plans to enroll 57 participants.